A detailed history of Summit Partners Public Asset Management, LLC transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Summit Partners Public Asset Management, LLC holds 21,318 shares of SRPT stock, worth $2.69 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
21,318
Holding current value
$2.69 Million
% of portfolio
0.15%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$113.33 - $163.85 $2.42 Million - $3.49 Million
21,318 New
21,318 $3.37 Million
Q3 2023

Nov 14, 2023

SELL
$102.5 - $123.59 $31.2 Million - $37.6 Million
-304,276 Reduced 87.29%
44,319 $5.37 Million
Q2 2023

Aug 14, 2023

BUY
$106.4 - $157.19 $19.2 Million - $28.4 Million
180,386 Added 107.24%
348,595 $39.9 Million
Q1 2023

May 15, 2023

BUY
$117.53 - $155.99 $143,269 - $190,151
1,219 Added 0.73%
168,209 $23.2 Million
Q4 2022

Feb 14, 2023

BUY
$100.86 - $132.13 $16.8 Million - $22.1 Million
166,990 New
166,990 $21.6 Million
Q1 2019

May 15, 2019

SELL
$106.67 - $151.68 $8.78 Million - $12.5 Million
-82,327 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$97.32 - $148.76 $121,941 - $186,396
1,253 Added 1.55%
82,327 $8.98 Million
Q3 2018

Nov 14, 2018

BUY
$115.31 - $161.51 $2.66 Million - $3.73 Million
23,074 Added 39.78%
81,074 $13.1 Million
Q2 2018

Aug 14, 2018

SELL
$71.74 - $153.69 $4.45 Million - $9.53 Million
-62,000 Reduced 51.67%
58,000 $7.67 Million
Q1 2018

May 15, 2018

SELL
$54.02 - $82.27 $1.89 Million - $2.88 Million
-35,000 Reduced 22.58%
120,000 $8.89 Million
Q4 2017

Feb 14, 2018

BUY
$47.64 - $56.75 $7.38 Million - $8.8 Million
155,000
155,000 $8.62 Million

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $11B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Summit Partners Public Asset Management, LLC Portfolio

Follow Summit Partners Public Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Summit Partners Public Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Summit Partners Public Asset Management, LLC with notifications on news.